Plain-English translation of NCT06587685 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atopic Dermatitis research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a medication called PG-011 Gel (3%) to see if it can help treat atopic dermatitis—a chronic skin condition that causes itching, redness, and inflammation. You would apply this medication to your skin twice daily for up to a year. The trial will measure how well the treatment works and check that it is safe to use long-term.
Atopic dermatitis can be difficult to manage and severely impact quality of life. This medication is being studied to offer patients a new, potentially more effective topical treatment option for mild to moderate cases.
You likely qualify if…
You likely don't qualify if…
You would apply the medication (or a placebo gel) to your affected skin twice daily for 8 weeks while being carefully monitored. After that, everyone moves to the active treatment for another 44 weeks, followed by a 2-week safety check-up. You'll have regular clinic visits to assess how your skin is improving and to watch for any side effects. In total, the study lasts about one year.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China